<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002678</url>
  </required_header>
  <id_info>
    <org_study_id>MY7</org_study_id>
    <secondary_id>CAN-NCIC-MY7</secondary_id>
    <secondary_id>NCI-V95-0713</secondary_id>
    <secondary_id>CDR0000064328</secondary_id>
    <nct_id>NCT00002678</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Patients With Multiple Myeloma</brief_title>
  <official_title>A COMPARATIVE STUDY OF DEXAMETHASONE VERSUS PREDNISONE (BOTH IN COMBINATION WITH MELPHALAN) AS INDUCTION THERAPY IN UNTREATED SYMPTOMATIC MYELOMA WITH AN ADDITIONAL ASSESSMENT OF DEXAMETHASONE VERSUS NO ADDITIONAL TREATMENT AS MAINTENANCE THERAPY IN NON-PROGRESSING PATIENTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Combining more than one drug may kill more tumor cells. It is not
      yet known which combination chemotherapy regimen is most effective in treating patients with
      multiple myeloma.

      PURPOSE: Randomized phase III trial to compare the effectiveness of various combination
      chemotherapy regimens in treating patients with multiple myeloma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Compare the overall survival of patients with previously untreated stage I-III multiple
           myelome treated with melphalan combined with dexamethasone or prednisone as induction
           therapy.

        -  Compare the overall survival of patients with stable or responding disease after
           induction treated with dexamethasone vs observation alone as maintenance therapy.

        -  Compare the time to progression, response rate, and quality of life of patients treated
           with these regimens.

        -  Compare the toxic effects of these regimens in these patients.

      OUTLINE: This is a randomized, multicenter study. Patients are stratified by center, stage (I
      or II vs III), creatinine (less than 2.0 mg/dL vs 2.0 mg/dL or greater), and intention to use
      prophylactic bisphosphonate (yes vs no).

        -  Induction: Patients are randomized to 1 of 4 treatment arms.

             -  Arms I and II: Patients receive induction comprising oral prednisone followed by
                oral melphalan on days 1-4.

             -  Arms III and IV: Patients receive induction comprising oral melphalan and oral
                dexamethasone (DM) on days 1-4 of all courses and DM on days 15-18 of courses 1-3.

      Induction for arms I-IV continues every 4 weeks for 12 courses in the absence of disease
      progression or unacceptable toxicity. Patients with stable or responding disease after
      induction proceed to maintenance therapy.

        -  Maintenance:

             -  Arms I and III: Patients undergo observation.

             -  Arms II and IV: Patients receive oral DM on days 1-4. Maintenance therapy continues
                every 4 weeks for arms II and IV and every 3 months for arms I and III in the
                absence of disease progression or unacceptable toxicity. Patients on arms I-IV who
                develop disease progression proceed to reinduction.

        -  Reinduction: Patients restart induction on the arm to which they were originally
           randomized. Reinduction continues every 4 weeks in the absence of stable response
           lasting 16 weeks, disease progression, or unacceptable toxicity. Patients who achieve a
           stable response lasting 16 weeks restart maintenance therapy. Patients who experience
           further disease progression during reinduction are taken off study.

      Quality of life is assessed at baseline, on day 1 of courses 1-3 and then every 3 courses
      during induction, and then every 3 months during maintenance therapy.

      Patients are followed every 6 months.

      PROJECTED ACCRUAL: A maximum of 600 patients will be accrued for this study within 6 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 1995</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2003</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>9 years</time_frame>
    <description>To compare overall survival between:
i) patients receiving melphalan-prednisone and those receiving melphalan-dexamethasone as induction therapy ii) patients maintained by dexamethasone and those on no additional treatment in the subgroup whose disease has not progressed at the time of the 12th induction cycle</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>9 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rates</measure>
    <time_frame>9 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>9 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>9 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">595</enrollment>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <arm_group>
    <arm_group_label>Melphan plus prednisone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>melphalan plus prednisone qd x 4 28 day cycles x 12 cycles; No treatment after stable response.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Melphan, prednisone pluse dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>melphalan plus prednisone qd x 4 28 day cycles x 12 cycles; dexamethasone qd x 4 q 28 days after non-progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexamethasone</intervention_name>
    <description>40 mg daily for four days given orally and repeated every 28 days should commence on day 29 of the twelfth cycle of induction therapy.</description>
    <arm_group_label>Melphan, prednisone pluse dexamethasone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <description>9 mg/m2 daily for 4 days given orally on an empty stomach every 4 weeks</description>
    <arm_group_label>Melphan plus prednisone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisone</intervention_name>
    <description>100 mg daily for 4 days given orally on a full stomach with each cycle of melphalan</description>
    <arm_group_label>Melphan plus prednisone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically proven previously untreated stage I-III multiple myeloma

               -  Patients with stage I disease must be symptomatic

          -  Must meet at least 1 of the following conditions:

               -  Plasma cells in osteolytic lesion or soft tissue tumor biopsy

               -  At least 10% plasmacytosis in bone marrow aspirate and/or biopsy

               -  Less than 10% plasma cells in bone marrow but at least 1 bony lesion

          -  Detectable serum M-component of IgG, IgA, IgD, or IgE

               -  If only light chain disease (urine M-protein) present, urinary excretion of light
                  chain (Bence Jones) protein must be at least 1.0 g/24 hours

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  ECOG 0-4

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Not specified

        Renal:

          -  Not specified

        Other:

          -  No other concurrent serious illness

          -  Concurrent diabetes allowed, at the discretion of the treating physician, if changes
             in insulin requirements can be managed

          -  No other prior or concurrent malignancy except curatively treated nonmelanomatous skin
             cancer or carcinoma in situ of the cervix

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  No concurrent immunizations

          -  No concurrent filgrastim (G-CSF) or other growth factors as prophylaxis

          -  Concurrent epoetin alfa for anemia allowed

        Chemotherapy:

          -  No prior chemotherapy

        Endocrine therapy:

          -  Prior dexamethasone or prednisone with radiotherapy for spinal cord compression
             allowed if cumulative dexamethasone dose no greater than 120 mg and cumulative
             prednisone dose no greater than 792 mg

          -  Prior or concurrent corticosteroids for hypercalcemia allowed

        Radiotherapy:

          -  See Endocrine therapy

          -  Prior focal radiotherapy allowed

          -  Concurrent focal radiotherapy during induction allowed

          -  Concurrent radiotherapy for palliation (e.g., painful osteolytic lesions or spinal
             cord compression) allowed

        Surgery:

          -  At least 2 years since prior surgery for radiologic or endoscopic diagnosis of gastric
             or duodenal ulcer

        Other:

          -  At least 2 years since prior medication for radiologic or endoscopic diagnosis of
             gastric or duodenal ulcer

          -  Prior or concurrent bisphosphonates for hypercalcemia allowed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chaim Shustik, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Royal Victoria Hospital - Montreal</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St. Mary's/Duluth Clinic Health System</name>
      <address>
        <city>Duluth</city>
        <state>Minnesota</state>
        <zip>55805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tom Baker Cancer Center - Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Cancer Agency - Centre for the Southern Interior</name>
      <address>
        <city>Kelowna</city>
        <state>British Columbia</state>
        <zip>V1Y 5L3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Cancer Agency</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Health Care - Vancouver</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>British Columbia Cancer Agency - Vancouver Island Cancer Centre</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8R 6V5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moncton Hospital</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 6ZB</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doctor Leon Richard Oncology Centre</name>
      <address>
        <city>Moncton</city>
        <state>New Brunswick</state>
        <zip>E1C 8X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint John Regional Hospital</name>
      <address>
        <city>Saint John</city>
        <state>New Brunswick</state>
        <zip>E2L 4L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newfoundland Cancer Treatment and Research Foundation</name>
      <address>
        <city>St. Johns</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1B 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nova Scotia Cancer Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>William Osler Health Centre</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6W 2Z8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Ontario-Hamilton Regional Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kingston Regional Cancer Centre</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7L 5P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Ontario-London Regional Cancer Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trillium Health Centre</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5B 1B8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Credit Valley Hospital</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5M 2N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southlake Regional Health Centre</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>L3Y 2P9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lakeridge Health Oshawa</name>
      <address>
        <city>Oshawa</city>
        <state>Ontario</state>
        <zip>L1G 2B9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Algoma District Medical Group</name>
      <address>
        <city>Sault Sainte Marie</city>
        <state>Ontario</state>
        <zip>P6B 1Y5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hotel Dieu Health Sciences Hospital - Niagara</name>
      <address>
        <city>St. Catharines</city>
        <state>Ontario</state>
        <zip>L2R 5K3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northeastern Ontario Regional Cancer Centre, Sudbury</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3E 5J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto East General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4C 3E7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Sunnybrook Regional Cancer Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital - Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Margaret Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Humber River Regional Hospital</name>
      <address>
        <city>Weston</city>
        <state>Ontario</state>
        <zip>M9N 1N8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Ontario - Windsor Regional Cancer Centre</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 2X3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital, PEI</name>
      <address>
        <city>Charlottetown</city>
        <state>Prince Edward Island</state>
        <zip>C1A 8T5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUS-Hopital Fleurimont</name>
      <address>
        <city>Fleurimont</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Charles Lemoyne</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de L'Enfant Jesus</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1J 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital du Saint-Sacrement, Quebec</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1S 4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allan Blair Cancer Centre</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T 7T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Shustik C, Belch A, Robinson S, Rubin SH, Dolan SP, Kovacs MJ, Grewal KS, Walde D, Barr R, Wilson J, Gill K, Vickars L, Rudinskas L, Sicheri DA, Wilson K, Djurfeldt M, Shepherd LE, Ding K, Meyer RM. A randomised comparison of melphalan with prednisone or dexamethasone as induction therapy and dexamethasone or observation as maintenance therapy in multiple myeloma: NCIC CTG MY.7. Br J Haematol. 2007 Jan;136(2):203-11.</citation>
    <PMID>17233817</PMID>
  </results_reference>
  <results_reference>
    <citation>Shustik C, Belch A, Robinson S, et al.: Dexamethasone (dex) maintenance versus observation (obs) in patients with previously untreated multiple myeloma: a National Cancer Institute of Canada Clinical Trials Group study: MY.7. [Abstract] J Clin Oncol 22 (Suppl 14): A-6510, 560s, 2004.</citation>
  </results_reference>
  <results_reference>
    <citation>Shustik C, Belch A, Meyer R, et al.: Melphalan-dexamethasone is not superior to melphalan-prednisone as induction therapy in multiple myeloma. [Abstract] Proceedings of the American Society of Clinical Oncology 20: A-1191, 2001.</citation>
  </results_reference>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>September 20, 2012</last_update_submitted>
  <last_update_submitted_qc>September 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

